Soft tissue sarcomas (STS) are a rare a highly heterogeneous set of malignant mesenchymal neoplasms. Histological grading plays a central role in the assessment and management of patients with STS, since histological gradeis prognostic, contributes to clinical staging, and is also predictive of chemotherapy responses so drives clinical decisionmaking on the use of adjuvant chemotherapy. Here we review the main histopathological grading systems andthe main considerations for the practising pathologist when grading STS. We highlight that histological STS gradingis not without its limitations, not least in classifying 50% of tumours as of uncertain behaviour (grade 2). However, recent developments in molecular risk stratification hold promise for molecular grading of STS with the ultimate goal of personalising therapy based on molecular profiles.